Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,276

Twist Bioscience Enhances DNA Storage Capabilities Through Agreement With Imagene SA

SAN FRANCISCO—( )—Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has entered into an agreement with Imagene SA, where Imagene will provide Twist with an encapsulation service to store DNA through its DNAshell® technology to store digital data encoded in DNA for thousands of years.

“We are happy to be partnering with Twist and providing them with our disruptive DNAshell® technology to safely store DNA with digital data encoded.” Tweet this

“This agreement with Imagene provides the next step in the continuum on DNA digital data storage and fits within our strategy to cover all aspects of the process efficiently to enable the development of DNA as a digital storage medium,” commented Emily Leproust, Ph.D., CEO of Twist Bioscience. “We believe the DNAshell ® technology allows us to encapsulate the DNA-stored digital data securely, protecting it for eternity from any elements including radiation, and eliminating the need for continued copying of digital data due to degradation experienced in other forms of storage today.”

AI Can Diagnose Like Doctors. But for Continued Progress, Research Standards Must Improve

The trawl found 20,500 articles tackling the topic, but shockingly, less than 1 percent of them were scientifically robust enough to be confident in their claims, say the authors. Of those, only 25 tested their deep learning models on unseen data, and only 14 actually compared performance with health professionals on the same test sample.

Nonetheless, when the researchers pooled the data from the 14 most rigorous studies, they found the deep learning systems correctly detected disease in 87 percent of cases, compared to 86 percent for healthcare professionals. They also did well on the equally important metric of excluding patients who don’t have a particular disease, getting it right 93 percent of the time compared to 91 percent for humans.

Ultimately, then, the results of the review are broadly positive for AI, but damning of the hype that has built up around the technology and the research practices of most of those trying to apply it to medical diagnosis.

Fruit flies live longer with combination drug treatment

A triple drug combination has been used to extend the lifespan of fruit flies by 48% in a new study led by UCL and the Max Planck Institute for Biology of Ageing.

The three drugs are all already in use as : lithium as a mood stabiliser, trametinib as a and rapamycin as an immune system regulator.

The findings, published in Proceedings of the National Academy of Sciences (PNAS), suggest that a combination treatment may one day be helpful at preventing in people.

Rapture of the nerds: will the Singularity turn us into gods or end the human race?

Circa 2012

Hundreds of the world’s brightest minds — engineers from Google and IBM, hedge funds quants, and Defense Department contractors building artificial intelligence — were gathered in rapt attention inside the auditorium of the San Francisco Masonic Temple atop Nob Hill. It was the first day of the seventh annual Singularity Summit, and Julia Galef, the President of the Center for Applied Rationality, was speaking onstage. On the screen behind her, Galef projected a giant image from the film Blade Runner: the replicant Roy, naked, his face stained with blood, cradling a white dove in his arms.

At this point in the movie, Roy is reaching the end of his short, pre-programmed life, “The poignancy of his death scene comes from the contrast between that bitter truth and the fact that he still feels his life has meaning, and for lack of a better word, he has a soul,” said Galef. “To me this is the situation we as humans have found ourselves in over the last century. Turns out we are survival machines created by ancient replicators, DNA, to produce as many copies of them as possible. This is the bitter pill that science has offered us in response to our questions about where we came from and what it all means.”

The Singularity Summit bills itself as the world’s premier event on robotics, artificial intelligence, and other emerging technologies. The attendees, who shelled out $795 for a two-day pass, are people whose careers depend on data, on empirical proof. Peter Norvig, Google’s Director of Research, discussed advances in probabilistic first-order logic. The Nobel prize-winning economist Daniel Kahneman lectured on the finer points of heuristics and biases in human psychology. The Power Point presentations were full of math equations and complex charts. Yet time and again the conversation drifted towards the existential: the larger, unanswerable questions of life.

For the September Journal Club we are taking a look at the new human trial data from the recent senolytics trial at the Mayo Clinic

Click on photo to start video.

A follow on study from their previous human trial targeting IPF. This time the researchers ran a study to see how senolytics influenced diabetic kidney disease and if it actually removes senescent cells in humans.

Senescent cells, which can release factors that cause inflammation and dysfunction, the senescence-associated secretory phenotype (SASP), accumulate with ageing and at etiological sites in multiple chronic diseases. Senolytics, including the combination of Dasatinib and Quercetin (D + Q), selectively eliminate senescent cells by transiently disabling pro-survival networks that defend them against their own apoptotic environment. In the first clinical trial of senolytics, D + Q improved physical function in patients with idiopathic pulmonary fibrosis (IPF), a fatal senescence-associated disease, but to date, no peer-reviewed study has directly demonstrated that senolytics decrease senescent cells in humans.

Reference

Hickson, L. J., Prata, L. G. L., Bobart, S. A., Evans, T. K., Giorgadze, N., Hashmi, S. K., … & Kellogg, T. A. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine.

Studying a cell’s crawling motion in a fluid

Cell motility, the spontaneous movement of cells from one location to another, plays a fundamental role in many biological processes, including immune responses and metastasis. Recent physics studies have gathered new evidence suggesting that mammalian cells do not only crawl on solid substrates, including complex 3D mediums of a tissues, but can also swim in fluids.

In a recent study, a team of researchers at the University Grenoble Alpes and CNRS (National Center of Scientific Research) tried to shed light on the mechanisms behind the onset of motility cells in suspension, which would occur if they were moving in fluids. Their paper, published in Physical Review Letters, presents a model that couples actin and myosin kinetics with , which they applied to a spherical and a non-spherical shape.

“Recent studies have suggested that adhesion is not necessary for cells to move in a three-dimensional environment, and have even shown that cells of the immune system can swim when suspended in a fluid,” the researchers who conducted the study told Phys.org via email.

Researchers synthesize ‘impossible’ superconductor

Researchers from the U.S., Russia, and China have bent the rules of classical chemistry and synthesized a “forbidden” compound of cerium and hydrogen—CeH9—which exhibits superconductivity at a relatively low pressure of 1 million atmospheres. The paper came out in Nature Communications.

Superconductors are materials capable of conducting an electric current with no resistance whatsoever. They are behind the powerful electromagnets in , maglev trains, MRI scanners, and could theoretically enable power lines that deliver electricity from A to B without losing the precious kilowatts to thermal dissipation.

Unfortunately, the superconductors known today can only work at very low temperatures (below −138 degrees Celsius), and latest record (−13 degrees Celsius) requires extremely high pressures of nearly 2 million atmospheres. This limits the scope of their possible applications and makes the available superconducting technologies expensive, since maintaining their fairly extreme operating conditions is challenging.

‘Revolution’ in prostate cancer care as off-label breast cancer drug doubles survival

A breast cancer drug has been used to double the survival of men with advanced prostate cancer, becoming the first successful precision medicine for the disease.

Doctors at the Royal Marsden Hospital who conducted the trial say the results amount to a “revolution” in prostate cancer care.

They conducted genetic testing on more than 4,400 patients to identify those with one or more of 15 types of DNA fault.